AKT Inhibition Gets Narrow Win in First-Line mCRPC

(MedPage Today) -- Adding ipatasertib to abiraterone (Zytiga) modestly improved oncologic outcomes for certain men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC), though at the cost of more toxicity...